Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor

Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied patients at rociletinib progression to explore resistance mechanisms. Among 12 patients with T790M-positive cancers at rocile...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Autores principales: Piotrowska, Zofia, Niederst, Matthew J., Karlovich, Chris A., Wakelee, Heather A., Neal, Joel W., Mino-Kenudson, Mari, Fulton, Linnea, Hata, Aaron N., Lockerman, Elizabeth L., Kalsy, Anuj, Digumarthy, Subba, Muzikansky, Alona, Raponi, Mitch, Garcia, Angel R., Mulvey, Hillary E., Parks, Melissa K., DiCecca, Richard H., Dias-Santagata, Dora, Iafrate, A. John, Shaw, Alice T., Allen, Andrew R., Engelman, Jeffrey A., Sequist, Lecia V.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497836/
https://ncbi.nlm.nih.gov/pubmed/25934077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0399
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares